MX2021012903A - Moduladores de la via de respuesta integrada al estres. - Google Patents
Moduladores de la via de respuesta integrada al estres.Info
- Publication number
- MX2021012903A MX2021012903A MX2021012903A MX2021012903A MX2021012903A MX 2021012903 A MX2021012903 A MX 2021012903A MX 2021012903 A MX2021012903 A MX 2021012903A MX 2021012903 A MX2021012903 A MX 2021012903A MX 2021012903 A MX2021012903 A MX 2021012903A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- stress response
- modulators
- integrated stress
- response pathway
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19170504 | 2019-04-23 | ||
| EP19216875 | 2019-12-17 | ||
| PCT/EP2020/061150 WO2020216766A1 (en) | 2019-04-23 | 2020-04-22 | Modulators of the integrated stress response pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012903A true MX2021012903A (es) | 2022-01-18 |
Family
ID=70289816
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012903A MX2021012903A (es) | 2019-04-23 | 2020-04-22 | Moduladores de la via de respuesta integrada al estres. |
| MX2024015479A MX2024015479A (es) | 2019-04-23 | 2021-10-21 | Moduladores de la via de respuesta integrada al estres |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024015479A MX2024015479A (es) | 2019-04-23 | 2021-10-21 | Moduladores de la via de respuesta integrada al estres |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12258338B2 (https=) |
| EP (1) | EP3959198A1 (https=) |
| JP (2) | JP7590343B2 (https=) |
| KR (1) | KR20220004105A (https=) |
| CN (1) | CN113993850B (https=) |
| AU (1) | AU2020261234B2 (https=) |
| BR (1) | BR112021020402A2 (https=) |
| CA (1) | CA3137213A1 (https=) |
| CL (1) | CL2021002772A1 (https=) |
| CO (1) | CO2021014292A2 (https=) |
| IL (1) | IL287379B2 (https=) |
| MX (2) | MX2021012903A (https=) |
| PE (1) | PE20220961A1 (https=) |
| SG (1) | SG11202111119PA (https=) |
| WO (1) | WO2020216766A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201245B (zh) | 2017-09-01 | 2024-04-05 | 戴纳立制药公司 | 化合物、组合物和方法 |
| CN111757739A (zh) | 2017-12-13 | 2020-10-09 | 普拉西斯生物技术有限责任公司 | 整合应激反应路径抑制剂 |
| AU2019282253A1 (en) | 2018-06-05 | 2020-11-26 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| SG11202108552QA (en) * | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| MX2021012904A (es) * | 2019-04-23 | 2022-01-18 | Evotec Int Gmbh | Moduladores de la via de respuesta al estres integrada. |
| WO2020252207A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| WO2021165927A1 (en) * | 2020-02-21 | 2021-08-26 | Wockhardt Bio Ag | 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents |
| CN115190813B (zh) | 2020-03-11 | 2024-10-15 | 埃沃特克国际有限责任公司 | 整合应激反应途径的调节剂 |
| EP4232153A1 (en) * | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| RS66455B1 (sr) | 2020-10-22 | 2025-02-28 | Evotec Int Gmbh | Modulatori puta integrisanog odgovora na stres |
| EP4232447A1 (en) | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| US20230083885A1 (en) * | 2021-04-02 | 2023-03-16 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| AU2023384649A1 (en) * | 2022-11-21 | 2025-05-22 | Shenzhen Zhongge Biological Technology Co., Ltd. | Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof |
| CN116854623B (zh) * | 2023-07-11 | 2025-08-05 | 齐鲁安替制药有限公司 | 一种阿维巴坦中间体的制备方法 |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6639761B1 (en) | 1999-12-02 | 2003-10-28 | Seagate Technology Llc | Micro-actuator damping and humidity protection |
| AU2001233044A1 (en) * | 2000-01-28 | 2001-08-07 | Akkadix Corporation | Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles |
| JP2007532672A (ja) | 2004-04-16 | 2007-11-15 | ウェイン ステート ユニバーシティ | 三置換２−ベンズヒドリル−５−ベンジルアミノ−テトラヒドロ−ピラン−４−オール、及び６−ベンズヒドリル−４−ベンジルアミノ−テトラヒドロ−ピラン−３−オール類縁体、及び新規３，６−二置換ピラン誘導体 |
| CA2904794C (en) | 2013-03-15 | 2021-11-23 | Peter Walter | Modulators of the eif2alpha pathway |
| MX2017000208A (es) | 2014-07-04 | 2017-05-01 | Lupin Ltd | Derivados de quinolizinona como inhibidores de pi3k. |
| WO2017046739A1 (en) | 2015-09-15 | 2017-03-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Imidazolidinone derivatives as inhibitors of perk |
| TW201722957A (zh) * | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產（第二）有限公司 | 化學化合物 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TWI763668B (zh) | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| KR20190015492A (ko) | 2016-06-08 | 2019-02-13 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화학적 화합물 |
| US20190298705A1 (en) * | 2016-06-08 | 2019-10-03 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| EP3649108A1 (en) | 2017-07-03 | 2020-05-13 | GlaxoSmithKline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| BR112020000122A2 (pt) | 2017-07-03 | 2020-07-07 | Glaxosmithkline Intellectual Property Development Limited | derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças |
| DE102017213834A1 (de) * | 2017-08-08 | 2019-02-14 | Robert Bosch Gmbh | Sende-/Empfangseinrichtung für ein Bussystem und Verfahren zur Reduzierung einer Schwingneigung beim Übergang zwischen unterschiedlichen Bitzuständen |
| CA3071024A1 (en) | 2017-08-09 | 2019-02-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN111201245B (zh) | 2017-09-01 | 2024-04-05 | 戴纳立制药公司 | 化合物、组合物和方法 |
| CA3080808A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| WO2019090074A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| WO2019090088A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| WO2019090090A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| JP2021501781A (ja) * | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| AU2018358157B2 (en) | 2017-11-02 | 2023-03-09 | Abbvie Inc. | Modulators of the integrated stress pathway |
| CN111757739A (zh) | 2017-12-13 | 2020-10-09 | 普拉西斯生物技术有限责任公司 | 整合应激反应路径抑制剂 |
| WO2019183589A1 (en) | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
-
2020
- 2020-04-22 EP EP20719452.3A patent/EP3959198A1/en active Pending
- 2020-04-22 JP JP2021562988A patent/JP7590343B2/ja active Active
- 2020-04-22 WO PCT/EP2020/061150 patent/WO2020216766A1/en not_active Ceased
- 2020-04-22 PE PE2021001762A patent/PE20220961A1/es unknown
- 2020-04-22 BR BR112021020402A patent/BR112021020402A2/pt unknown
- 2020-04-22 CN CN202080045788.1A patent/CN113993850B/zh active Active
- 2020-04-22 US US17/605,037 patent/US12258338B2/en active Active
- 2020-04-22 IL IL287379A patent/IL287379B2/en unknown
- 2020-04-22 MX MX2021012903A patent/MX2021012903A/es unknown
- 2020-04-22 KR KR1020217037824A patent/KR20220004105A/ko active Pending
- 2020-04-22 CA CA3137213A patent/CA3137213A1/en active Pending
- 2020-04-22 SG SG11202111119PA patent/SG11202111119PA/en unknown
- 2020-04-22 AU AU2020261234A patent/AU2020261234B2/en active Active
-
2021
- 2021-10-21 MX MX2024015479A patent/MX2024015479A/es unknown
- 2021-10-22 CL CL2021002772A patent/CL2021002772A1/es unknown
- 2021-10-26 CO CONC2021/0014292A patent/CO2021014292A2/es unknown
-
2024
- 2024-11-13 JP JP2024198168A patent/JP2025024086A/ja active Pending
-
2025
- 2025-02-19 US US19/057,900 patent/US20250188071A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020261234A1 (en) | 2021-11-11 |
| CN113993850B (zh) | 2024-03-29 |
| WO2020216766A1 (en) | 2020-10-29 |
| IL287379B1 (en) | 2025-07-01 |
| AU2020261234B2 (en) | 2026-02-05 |
| MX2024015479A (es) | 2025-02-10 |
| BR112021020402A2 (pt) | 2021-12-07 |
| CA3137213A1 (en) | 2020-10-29 |
| PE20220961A1 (es) | 2022-06-10 |
| JP7590343B2 (ja) | 2024-11-26 |
| US12258338B2 (en) | 2025-03-25 |
| JP2025024086A (ja) | 2025-02-19 |
| EP3959198A1 (en) | 2022-03-02 |
| KR20220004105A (ko) | 2022-01-11 |
| CN113993850A (zh) | 2022-01-28 |
| CL2021002772A1 (es) | 2022-07-29 |
| CO2021014292A2 (es) | 2022-04-29 |
| US20250188071A1 (en) | 2025-06-12 |
| US20220227747A1 (en) | 2022-07-21 |
| JP2022530049A (ja) | 2022-06-27 |
| IL287379B2 (en) | 2025-11-01 |
| IL287379A (en) | 2021-12-01 |
| SG11202111119PA (en) | 2021-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024015479A (es) | Moduladores de la via de respuesta integrada al estres | |
| MX2022009243A (es) | Moduladores de la via de respuesta integrada al estres. | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| MX2020001776A (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. | |
| PH12022550980A1 (en) | Small molecule degraders of helios and methods of use | |
| MY204171A (en) | Novel sulfonamide carboxamide compounds | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| EP4360707A3 (en) | Compositions for treating spinal muscular atrophy | |
| EP4252848A3 (en) | Oxysterols and methods of use thereof | |
| CR20230143A (es) | Degradadores de moléculas pequeñas de piperidinilo de helios y procedimientos de uso | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| MX2020006459A (es) | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. | |
| MX2021004940A (es) | Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos. | |
| MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| PH12020550168A1 (en) | Griseofulvin compound and pharmaceutical use thereof | |
| NZ762437A (en) | Novel heterocyclic compounds as cdk8/19 inhibitors | |
| MX2022011143A (es) | Moduladores de la via de respuesta integrada al estres. | |
| GEP20237459B (en) | Thiadiazine derivatives | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| MX2023004626A (es) | Moduladores de la via de respuesta integrada al estres. | |
| MX2023004677A (es) | Moduladores de la via de respuesta integrada al estres. | |
| SG10201907026RA (en) | Prevention or Treatment of Uratic or Gouty Diseases |